Comparative Pharmacology
Head-to-head clinical analysis: AMBIEN CR versus EQUAGESIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBIEN CR versus EQUAGESIC.
AMBIEN CR vs EQUAGESIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMBIEN CR's active ingredient is zolpidem, a non-benzodiazepine hypnotic that binds selectively to the benzodiazepine-1 (BZ1) receptor subtype on the GABA-A receptor complex, potentiating GABAergic inhibition and promoting sleep.
Equagesic is a combination of aspirin and meprobamate. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and COX-2, reducing prostaglandin synthesis. Meprobamate potentiates GABA-A receptor activity, producing anxiolytic and sedative effects.
12.5 mg orally once daily immediately before bedtime; lower dose of 6.25 mg may be considered. Not to exceed 12.5 mg per day.
Adults: 1 tablet (200 mg meprobamate, 25 mg ethoheptazine citrate, 325 mg aspirin) orally 3 or 4 times daily.
None Documented
None Documented
Zolpidem immediate-release: ~2.5 h (range 1.4–3.8 h); modified-release (Ambien CR): ~2.8 h (range 1.6–4.5 h). Clinical note: Half-life increased in hepatic impairment and elderly.
Meprobamate: 10-12 hours in healthy adults, prolonged in liver disease; Aspirin: low doses 2-3 hours, anti-inflammatory doses 15-30 hours (saturable elimination).
Primarily renal (80% as metabolites, <5% unchanged), minor fecal (<10%)
Meprobamate: renal (10% as unchanged drug, 80-90% as hydroxylated metabolites); Aspirin: renal (dose-dependent, 50-80% as salicyluric acid, 10% as unchanged salicylate at acidic pH).
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic